abstract |
The present invention relates to compositions and methods for predicting treatment susceptibility to trastuzumab in breast cancer patients, specifically, SEQ ID NOs: 1 to 9, SEQ ID NOs: 11 to 19, and SEQ ID NOs: 21 to 23 described in the sequence table. A polynucleotide comprising a base sequence to be displayed, or a base sequence of which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising at least 16 consecutive bases, or a base sequence complementary thereto A composition, kit, DNA chip, and method for predicting therapeutic susceptibility to trastuzumab using polynucleotides as indicators of increase or decrease in the amount of expression of Her2 protein. |